Two timelines patients often confuse

Most patients asking how long ChondroFiller lasts are actually asking two separate questions at once — and conflating the answers is the most common source of confusion about this treatment.

The first timeline belongs to the collagen scaffold itself. After placement under ultrasound guidance, the Type I collagen matrix biodegrades over approximately 6–24 months. That process is not a flaw; it is the design. Think of building scaffolding: once the structure beneath it is sound, the scaffolding is removed because it is no longer needed.

The second timeline belongs to the repair tissue the scaffold creates. ChondroFiller works through acellular matrix-induced chondrogenesis — the collagen matrix acts as a recruitment signal, drawing the patient's own progenitor cells into the defect, where they differentiate and form hyaline-like repair tissue. By the time the scaffold has fully degraded, that tissue is already established and maturing independently. The product supports the body's own repair processes; it is the patient's cells, not the scaffold material itself, that provide the lasting benefit.

Published data across knee, hip, and small-joint cohorts support 1–5 years of durable benefit from a single course of treatment. Scaffold biodegradation and clinical durability run on different clocks — and understanding that distinction is the starting point for realistic expectations.

What the clinical data show at 3–5 years

The most cited knee-specific dataset is the Jerosch post-market clinical follow-up (PMCF) study, referenced in the manufacturer's 2025 Clinical Evaluation Report. It records a mean IKDC improvement of 32.4 points at 36 months, with patients reaching an absolute score of approximately 80.1 out of 100 from a baseline of roughly 48. The Minimal Clinically Important Difference (MCID) for IKDC — the threshold at which a patient perceives a meaningful functional benefit — is 16.7 points; the 36-month gain is approximately double that figure.

Equally telling is the trajectory over time. Comparing the 36-month result with mean 12-month IKDC improvements across four independent prospective knee cohorts (approximately 30 points at one year) shows the gains are stable to slightly improving, not regressing. The physical resorption of the scaffold and the direction of clinical benefit are not moving in the same direction — a finding that underpins the two-timeline distinction described above.

The longest published follow-up to date comes from the hip. Mazek 2021 (PMC8460160) prospectively tracked 26 patients for 12 to 60 months following ChondroFiller placement for focal articular cartilage defects. Of 21 evaluable patients, 17 recorded good or excellent outcomes at the three-, four-, and five-year assessments consecutively.

Across the combined knee, hip, and small-joint evidence base, 70–85% of suitable patients maintain meaningful symptom relief at three to five years. That is a consistent population-level range drawn from multiple independent cohorts — not a predicted individual outcome.

MOCART scores add a structural dimension to these functional results. MOCART is an MRI-based measure of how completely repair tissue fills and integrates within the original defect; scores in the 70–87 range, as observed in suitable ChondroFiller patients, are consistent with hyaline-like repair rather than the fibrocartilaginous tissue that tends to form after simpler interventions such as microfracture. Structural quality of this kind is one reason the clinical benefit appears sustained rather than transient. All of this evidence derives from observational cohort studies — a design limitation that shapes how confidently the figures can be extrapolated.

Factors that affect how long results last

Four variables have the greatest bearing on how long any individual patient's benefit holds, and they span biology, behaviour, and technique.

Existing osteoarthritis grade is the single strongest negative predictor. In the Mazek 2021 hip cohort, patients with Tönnis grade 2–3 osteoarthritis recorded poor outcomes, whilst those with focal, well-defined defects fared well at five years. ChondroFiller is designed for focal cartilage defects of up to 6 cm² — it is not suited to the diffuse, bone-on-bone wear of advanced OA, where the conditions for stable scaffold integration are absent.

Post-injection loading discipline is the most directly modifiable factor. A protected weight-bearing period of 4–6 weeks is protocol-critical: applying mechanical load before repair tissue has established may disrupt scaffold integration and compromise the repair. This phase is within the patient's control and may materially affect how durable the result proves to be.

Application precision influences the quality of tissue that forms at the defect site. The 2025 Demmer wrist study (PMC12498443) found that overfilling a defect — placing more scaffold material than the space requires — produced fibrous rather than hyaline-like tissue. Flush application, where the scaffold sits level with the surrounding cartilage surface, produced significantly better outcomes (median Outerbridge score 1.5 versus 3, P=0.006). Exact placement is therefore not a minor technical detail.

Joint and defect type shapes how confidently published figures can be applied to a specific case. Evidence is most extensive for the knee and hip; wrist data are emerging and promising; ankle and other small-joint cohorts remain smaller.

Whether a patient's defect profile — size, location, surrounding OA grade, and joint involved — fits within this evidence base is precisely what a pre-treatment imaging review and specialist evaluation is there to establish.

How duration compares with other injection options

Hyaluronic acid (HA) viscosupplementation is absorbed within 4–6 months of injection and typically requires repeat courses to sustain symptom relief. It works through lubrication and short-term anti-inflammatory effects rather than structural repair — so its 'duration' reflects how long the fluid persists, not how long any tissue change lasts. That is a fundamentally different question from how long a regenerative scaffold holds, which is why direct duration comparisons between HA and ChondroFiller risk conflating unlike things.

For patients who are not suitable for injection therapy and move on to surgical alternatives, the picture shifts again. Microfracture and ACI/MACI are distinct pathways from the current ultrasound-guided injection service, but their long-term reoperation rates provide a useful reference point: cohort data record figures of up to 41% for microfracture and up to 37% for ACI/MACI. ChondroFiller cohort data place the comparable figure at approximately 3–8%. These numbers come from separate cohorts with different patient profiles, not from a head-to-head randomised trial, so they should be read as indicative rather than definitive. No direct RCT comparison of ChondroFiller against ACI/MACI on long-term outcomes currently exists.

What the comparison does usefully illustrate is that a lower reoperation burden over a 3-year horizon is possible with a single-course injectable pathway for appropriate candidates — but 'appropriate' is the operative word. Defect size, OA grade, and individual treatment goals determine which option, if any, is realistic. Identifying that fit is what a specialist assessment is for.

Honest limits of the current evidence

The most important single caveat is one of duration, not quality: the longest published follow-up reaches five years, from the Mazek 2021 hip cohort, with three-year knee data as the headline figure. No published evidence currently extends beyond that horizon. Whether a second treatment course becomes necessary after five or more years — and for which patients — remains a genuinely open question.

The evidence base itself is observational throughout. The outcome figures discussed earlier come from post-market cohort studies of suitable candidates treated under real-world conditions — clinically meaningful data, but not the same as a large randomised controlled trial with a blinded control group. That distinction is worth holding in mind when interpreting success-rate percentages or IKDC improvement scores: they reflect outcomes in well-selected cohorts, not a population-wide average.

On regulatory status: ChondroFiller holds CE-marking as a Class III medical device and has been in clinical use since 2013. Its complaint rate across the published surveillance record is approximately 0.06%. It does not hold FDA approval. For patients in the UK, CE-marking is the applicable standard; those researching treatment options from outside Europe should clarify the regulatory position with their treating clinician.

Taken together, these are calibrations rather than disqualifications — the clinical signal is real, but the evidence does not yet extend far enough to answer every question a patient might reasonably ask.

Deciding whether ChondroFiller is right for you

Suitability for ChondroFiller injection ultimately comes down to three clinical variables: defect size and location, OA grade, and the condition of the surrounding tissue. A specialist assessment — including an imaging review — is the step that maps those variables to the durability picture the article has set out.

Three questions are worth preparing before that appointment:

• What is my defect size and OA grade, and do they fall within the indicated range?
• Am I a candidate for ChondroFiller injection given my joint and overall health profile?
• What does the post-injection loading protocol involve, and are there circumstances in which it needs to be modified?

The evidence reviewed here has a concrete bottom line: a mean 32-point IKDC improvement sustained at three years, with 70–85% of well-selected patients maintaining meaningful symptom relief across knee and hip cohorts. Whether your profile places you in that well-selected group is precisely what the consultation is designed to establish. Search MSK lists specialists across the UK who offer ChondroFiller injection — filter by region and specialty to find one with experience in your joint and situation.